This post is presented by our media partner Psychedelic News Wire
View the original article here.
Research in the psychedelic field has flourished in 2023, with the latest studies showing that psilocybin may be legalized in a couple of years. Below, we look at key clinical studies that suggest optimal psilocybin dosing for mental health conditions such as depression.
COMP360 Psilocybin therapy trial
COMP360 is a synthetic psilocybin formulation developed by Compass Pathways PLC (NASDAQ: CMPS). The company, in partnership with Sunstone Therapies, recently carried out a phase 2 trial involving the use of their COMP360 psilocybin therapy on cancer patients who suffered from major depressive disorder.
The researchers determined that with a single 25mg dose of psilocybin, more than 50% of the patients remained in remission from their depression for more than a year after the dose’s administration. The researchers reported their findings in “JAMA Oncology” earlier this year.
Compass Pathways selective serotonin reuptake inhibitor exploratory study
Compass also carried out a phase 2 study that looked into the use of psilocybin in conjunction with selective serotonin reuptake inhibitors (SSRIs) to help manage depression. The company determined that administering a 25mg psilocybin dose as well as SSRIs while also offering psychological support showed improvements in patients with treatment-resistant depression.
In its report, the researchers noted that SSRIs may not interfere with COMP360’s therapeutic effect.
Nature Medicine’s trial on managing eating disorders
“Nature Medicine” recently carried out an open-label study that investigated the effects of administering a single 25mg COMP360 psilocybin dose on female patients who suffered from anorexia.
The researchers, led by Dr. Stephanie Knatz Peck and Dr. Walter Kaye from University of California San Diego School of Medicine, observed significant reductions in anorexia psychopathology following three months of treatment. They also observed substantial reductions in weight and shape concerns, with the participants themselves revealing that they had observed positive shifts in their quality of life as well as personal identity.
Cybin’s double dose of psilocybin for managing depression
The biopharmaceutical company recently announced interim results from a phase 2 trial that evaluated the use of its synthetic psilocybin formulation (CYB003) in treating major depressive disorder.
For the trial, one dose of 12mg was administered to patients, with researchers observing significant reductions in symptoms. In their report, the researchers noted that their findings suggested that CYB003 was effective in treating depression, adding that it outpaced conventional treatments within three weeks.
Sheppard Pratt Hospital’s trial on bipolar disorder
Earlier this year, Dr. Scott Aaronson at the aforementioned facility led a trial on the use of psilocybin in managing bipolar II depression.
During this trial period, bipolar patients were required to discontinue the use of their standard medications, after which they each received a single 25mg dose of psilocybin. The researchers observed a notable decline in depression severity, noting that after three months, more than 70% of the patients remained in remission with no increase in mania/hypomania or suicidality.
These studies, along with several others, are bringing various psychedelics closer to FDA approval, and patients could soon benefit from these novel treatments.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
This post was originally published by our media partner here.
